'Standard treatment' presentation slideshows

Zarnestra NDA 21824

Zarnestra NDA 21824. Qin Ryan MD, PhD DODP/CDER/FDA. Outline. Regulatory Background Clinical Overview and Proposed Indication CTEP-20 Design CTEP-20 Efficacy CTEP-20 Safety Summary. Regulatory Background. Regulatory Background.

751 views • 55 slides

SPINAL DEFORMITIES

SPINAL DEFORMITIES. Dr. ABDULMONEM ALSIDDIKY , MD , SSCO. Assistant Professor & Consultant pediatric Ortho.& Spinal Deformities The Director of Research Chair of Spinal Deformities KSU,KKUH Riyadh , S audi A rabia . NORMAL SPINE ALLIGNMENT. FRONTAL PLANE STRAIGHT

970 views • 44 slides

Chairperson Dr. Satya Ranjan Sutradhar Associate Professor & Head Department of Medicine, MMC

Comparison of short-course multidrug treatment with standard therapy for Visceral Leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Chairperson Dr. Satya Ranjan Sutradhar Associate Professor & Head Department of Medicine, MMC Speaker

565 views • 38 slides

Capital Region Family Medicine Conference September 8, 2012

Capital Region Family Medicine Conference September 8, 2012. Primary Palliative Care. Diagnosis ------- ? Chronic Illness ----? Death Curative Efforts ---------------------? Life Prolonging Measures ----------------------------------------?

489 views • 38 slides

Study Designs for Analytic Epidemiology

Study Designs for Analytic Epidemiology. Session 3, Part 2. Learning Objectives Session 3, Part 2. Define analytic epidemiology List 3 types of observational study designs. Overview Session 3, Part 2. Review of descriptive vs. analytic epidemiology Components of analytic epidemiology

862 views • 33 slides

William U. Shipley, MD, FASTRO Massachusetts General Hospital Harvard Medical School

360 views • 25 slides

RTI Process

642 views • 22 slides

Overview: AIDS Clinical Group Network (ACTG), Clinical Trials

Overview: AIDS Clinical Group Network (ACTG), Clinical Trials. Presenters: Charles Scott Ashley Young Jamal H.N. Hailey Ken Lazarus Bruce Mandela. AIDS Clinical trials group HTTPS://ACTGNETWORKK.ORG . The mission of the AIDS Clinical Trials Group (ACTG) Network is :

392 views • 20 slides

Overview of strategy for FY 14

Overview of strategy for FY 14. Myanmar. CAP-TB: Goal. To reduce the incidence and mortality from MDR TB in Myanmar In partnership with National Tuberculosis Programme. CAP-TB Strategy for FY14. Evaluate implementation to date (FY12-FY13)

205 views • 13 slides

Exercise 1

Exercise 1. You have a clinical study in which 10 patients will either get the standard treatment or a new treatment Randomize which 5 of the 10 get the new treatment so that all possible combinations can result. Use Excel or R or another formal randomization method.

258 views • 12 slides

Restrictive Lung Disease and Breathing Retraining

Restrictive Lung Disease and Breathing Retraining. Counce , Hirsch, Plummer, Reid. PICO. P Patients with restrictive lung disease I Standard treatment + breathing retraining C Standard treatment O Reducing dyspnea. Restrictive Lung Disease/Dysfunction. Reduced

722 views • 12 slides

Ethical Issues in Pediatric Research: Placebo controlled trials for gastoesophogeal reflux

Ethical Issues in Pediatric Research: Placebo controlled trials for gastoesophogeal reflux. Benjamin Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department of Clinical Bioethics, Warren G Magnuson Clinical Center National Institutes of Health.

323 views • 9 slides

Ethical Issues

Ethical Issues. Jewish Chronic Disease Hospital. In 1963, studies were undertaken at New York City's Jewish Chronic Disease Hospital to develop information on the nature of the human transplant rejection process.

530 views • 9 slides

555 views • 9 slides

Hepatitis C Last updated May 2013

Hepatitis C Last updated May 2013. Hepatitis C virus (1). Virus first identified in 1989 Routine screening of blood started in 1991 Many people were infected through contaminated blood/blood products prior to this Most new cases in developed countries are in injecting drug users

209 views • 9 slides

Unit Based Champions Infection Prevention eBug Bytes

287 views • 9 slides

Comments on talks

183 views • 9 slides

Mesothelioma: your questions and future treatment options

Mesothelioma: your questions and future treatment options. Susie Harden 1/4/11. Future possibilities in Cambridge. First line studies Second line studies Phase 1 studies Biobank: potential for individually tailored treatments in the future?. First line studies coming soon.

189 views • 6 slides

Objectives

A RANDOMIZED CONTROLLED TRIAL USING VITAMIN K AS ADJUVANT TREATMENT FOR BENIGN CAUSES OF MENORRHAGIA. Loo CV 1 , Noor Azmi MA 1 , Marzuki Isahak 2 1 Dept of O&G, University of Malaya, Kuala Lumpur 50603, Malaysia.

177 views • 1 slides

TRANSFER-AMI

TRANSFER-AMI. Primary endpoint: death, MI, HF, severe recurrent ischemia, or shock 11.0% in pharmacoinvasive arm vs. 17.2% in standard treatment arm Reinfarction: 3.4% vs. 5.7% (p = 0.06) Recurrent ischemia: 0.2% vs. 2.1% (p = 0.003). (p = 0.004). (p = 0.39). Pharmacoinvasive arm (n = 537).

232 views • 1 slides